Square Pharmaceuticals PLC. (DSE:SQURPHARMA)
Bangladesh flag Bangladesh · Delayed Price · Currency is BDT
225.70
-0.40 (-0.18%)
At close: Feb 26, 2026

DSE:SQURPHARMA Ratios and Metrics

Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Feb '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
200,072185,180186,953185,977192,094191,030
Market Cap Growth
3.77%-0.95%0.52%-3.18%0.56%31.17%
Enterprise Value
130,119126,115130,781132,967141,464147,209
Last Close Price
225.70197.14189.15178.84176.04170.40
PE Ratio
7.717.738.939.8010.5811.98
Forward PE
7.007.258.309.109.9310.40
PS Ratio
2.442.432.673.063.343.77
PB Ratio
1.391.321.491.611.832.10
P/TBV Ratio
1.391.321.491.611.832.10
P/FCF Ratio
13.3116.6513.0332.7128.7126.61
P/OCF Ratio
9.2510.7010.0921.7614.9217.40
PEG Ratio
-0.680.680.700.710.69
EV/Sales Ratio
1.591.651.872.192.462.90
EV/EBITDA Ratio
4.835.846.457.007.578.58
EV/EBIT Ratio
5.266.507.287.978.399.64
EV/FCF Ratio
8.6611.349.1223.3921.1420.51
Debt / Equity Ratio
0.000.010.010.020.020.00
Debt / EBITDA Ratio
0.020.040.070.100.100.01
Debt / FCF Ratio
0.030.070.100.350.290.01
Net Debt / Equity Ratio
-0.49-0.46-0.48-0.46-0.49-0.53
Net Debt / EBITDA Ratio
-2.92-2.99-2.95-2.77-2.75-2.79
Net Debt / FCF Ratio
-4.65-5.81-4.17-9.27-7.68-6.67
Asset Turnover
0.530.550.550.520.560.57
Inventory Turnover
3.083.153.033.183.723.94
Quick Ratio
3.8610.2210.7013.2914.3014.56
Current Ratio
4.7312.8013.4816.6717.0317.33
Return on Equity (ROE)
19.01%18.03%17.36%17.22%18.52%18.96%
Return on Assets (ROA)
8.84%8.67%8.83%8.93%10.17%10.77%
Return on Invested Capital (ROIC)
20.41%20.02%20.86%21.41%25.42%26.37%
Return on Capital Employed (ROCE)
15.00%13.80%14.10%14.20%15.60%16.50%
Earnings Yield
12.97%12.94%11.19%10.21%9.45%8.35%
FCF Yield
7.51%6.01%7.67%3.06%3.48%3.76%
Dividend Yield
5.32%6.09%5.82%5.87%5.68%3.52%
Payout Ratio
37.44%40.51%44.32%46.38%29.20%24.60%
Total Shareholder Return
5.32%6.09%5.82%5.87%5.68%3.52%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.